Skip to main content
. 2019 Jan 22;21(6):730–741. doi: 10.1093/neuonc/noz015

Fig. 5.

Fig. 5

Intracranial GL261 TILs and immunosuppressive cells after combination treatment of TMZ and PD-1 antibody. (A) No difference in CD3+ TILs was observed between groups treated with SD or MD TMZ/PD-1 antibody. (B) TILs in animals treated with SD TMZ/PD-1 antibody had significantly higher LAG-3 expression (2.3-fold, P = 0.018) compared with MD TMZ/PD-1 animals. There was a trend for increased TIM-3 in the SD TMZ/PD-1 antibody group (1.3-fold P = 0.4) as well. (C–E) GREAT mice underwent GL261 tumor implantation and treatment with TMZ and PD-1 antibody. Activated T cells as measured by YFP expression (IFN-γ expression) were increased within the tumors in the MD/PD-1 antibody group (14-fold YFP+ CD3/CD3 T cells, and 12-fold YFP+ CD4/CD4 T cells, P < 0.05). No differences in the YFP+ CD8 T cells were found between treatment groups (P = 0.8948; F–H). Flow cytometry was performed on intratumoral cells expressing MDSCs (CD11b+/Ly6G/6c+) or macrophages (CD11b+/F480+). The tumor infiltrating MDSCs and macrophages were not different. There was a trend for an increase (5.5-fold, P = 0.07302) in arginase-1 expressing macrophages in the SD/PD1 antibody group. n = 5 per group.